Hypothesis

Germ-line p53 Mutations Predispose to a Wide Spectrum of Early-onset Cancers

Kim E. Nichols, David Malkin, Judy E. Garber, Joseph F. Fraumeni, Jr., and Frederick P. Li


title

Abstract

Germ-line p53 mutations are associated with dominantly inherited Li-Fraumeni syndrome (LFS), which features early-onset sarcomas of bone and soft tissues, carcinomas of the breast and adrenal cortex, brain tumors, and acute leukemias. However, carriers of germ-line p53 mutations may also be at increased risk of other cancers. To clarify the tumor spectrum associated with inherited p53 mutations, we examined cancer occurrences among our series of 45 families, plus 140 other affected cases and kindreds reported in the literature. The analyses included all cancers in patients with a germ-line p53 mutation and their first-degree relatives with nearly 50% likelihood of being a carrier. Data were abstracted on tumor types and ages at diagnosis in eligible family members, and duplicate reports were excluded. Among 738 evaluable cancers, 569 (77%) were the six tumor types (breast and adrenal cortex, brain tumors, and acute leukemias, and brain tumors). In addition, fragmentary data suggest that carriers of germ-line p53 mutations might be susceptible to other forms of cancer (4–6, 9, 10). Fuller understanding of the neoplastic manifestations of germ-line p53 mutations would be useful for genetic counseling, cancer surveillance, and early interventions in carriers. Our analyses of 185 affected cases and kindreds support the hypothesis that carriers of germ-line p53 mutations are prone to a wider spectrum of tumors than recognized previously (1–83).

Introduction

Germ-line p53 mutations have been identified in the majority of families with dominantly inherited LFS, which predisposes individuals to diverse neoplasms at early ages (1–8). Patients with LFS are especially prone to carcinomas of the breast and adrenal cortex, sarcomas of the soft tissues and bone, acute leukemias, and brain tumors. In addition, fragmentary data suggest that carriers of germ-line p53 mutations might be susceptible to other forms of cancer (4–6, 9, 10). Fuller understanding of the neoplastic manifestations of germ-line p53 mutations would be useful for genetic counseling, cancer surveillance, and early interventions in carriers. Our analyses of 185 affected cases and kindreds support the hypothesis that carriers of germ-line p53 mutations are prone to a wider spectrum of tumors than recognized previously (1–83).

Materials and Methods

At DF/NCI, we have identified 45 families with LFS and germ-line p53 mutations (1–8). Surviving relatives provided detailed family histories of cancer, and medical and pathology records were reviewed to determine primary site, histology, and age at diagnosis of each neoplasm. In addition, review of the literature through 1999 identified cancer occurrences and ages at diagnosis in 140 other patients and multicase families with germ-line p53 mutations (9–83). Some families were reported more than once as additional cancers were diagnosed, and duplicate reports were eliminated from the analysis.

We examined the distribution of tumor types and ages at cancer diagnosis in carriers of germ-line p53 mutations, as well as in their affected first-degree relatives who were not genotyped. These relatives have nearly a 50% likelihood of carrying the mutation because published reports show that 80–95% of germ-line p53 mutations were inherited from a carrier-parent (7, 13, 72). For cases with multiple primary cancers, each neoplasm was counted in the analysis. Medians and ranges of age at cancer diagnosis and tumor site distribution in study subjects were compared with corresponding cancer incidence data of the United States population-based SEER Program (84).

Results

A total of 738 evaluable cancers were identified in the 185 patients and families with germ-line p53 mutations. Members of these kindreds developed 224 cancers (30%) before age 20 years and 265 cancers (36%) in the third and fourth decades of life. None of the p53 carriers and only 10 of their first-degree relatives (1.3%) developed tumors after 65 years of age, when cancers are most common in the general population (84).

The abbreviations used are: LFS, Li-Fraumeni syndrome; SEER, Surveillance, Epidemiology, and End Results; DF/NCI, Dana Farber Cancer Institute/National Cancer Institute.

Received 5/3/00; revised 11/20/00; accepted 11/22/00.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by the Liberty Mutual Group and The Starr Foundation (F. P. L.), and the National Cancer Institute of Canada with funds from the Terry Fox Foundation (D. M.).

2 F. P. L. is a Harry and Elsa Jiler American Cancer Society Clinical Research Professor.

3 To whom requests for reprints should be addressed, at Dana Farber Cancer Institute, Smith 201, 44 Binney Street, Boston, MA 02115. Phone: (617) 632-2508; Fax: (617) 632-3161; E-mail: frederick_lidfciharvard.edu.

4 The abbreviations used are: LFS, Li-Fraumeni syndrome; SEER, Surveillance, Epidemiology, and End Results; DF/NCI, Dana Farber Cancer Institute/National Cancer Institute.

Vol. 10, 83–87, February 2001 Cancer Epidemiology, Biomarkers & Prevention 83

Downloaded from cebp.aacrjournals.org on September 22, 2021. © 2001 American Association for Cancer Research.
Hypothesis: Tumor Spectrum in LFS

numbers of other neoplasms. Their first-degree relatives with a cases), ovary (8 cases), colon and rectum (7 cases) and smaller
tumors developed carcinomas of the lung (11 cases), stomach (8 
(2); and 23 other neoplasms, including rare carcinomas of the gall bladder, ampulla of Vater, ureter, and testis, and Wilms’ tumor (1 each).

$p53$ occurred in their first-degree relatives. Carriers of 
curred in

associated with LFS (Table 2). Sixty of these neoplasms oc-
acute leukemias (20) at early ages.

(115), bone sarcomas (89), adrenocortical carcinomas (32), and

breast cancers (189), soft tissue sarcomas (124), brain tumors 
first-degree relatives. The component tumors of LFS included 
neoplasms in 
tumors of LFS accounted for 569 cancers (77%), including 382 
and 296 cancers in their first-degree relatives with a nearly 50% 
likelihood of carrying the mutation (Table 1). The component 

and 296 cancers in their first-degree relatives with a nearly 50% 
likelihood of carrying the germ-line mutation. There were 442 cancers in 

Relatives with nearly 50% likelihood of a germ-line $p53$ mutation are parents, siblings, and offspring of carriers.

Other cancers include: carcinomas of the bladder (3), kidney (2), esophagus (3), and unknown primary site (2); hepatoblastoma (2); neuroblastoma (2); mesothelioma 

$p53$ risk is 73% among males and nearly 100% among females who 
are prone to breast cancer. The virtual absence of tumors in $p53$ mutation carriers after age 65 years might be due to their high 
cancer mortality in childhood and early adulthood or to their 
reluctance to be tested and found to have transmitted the germ-
cancer mortality in childhood and early adulthood or to their 
reluctance to be tested and found to have transmitted the germ-
line mutation. Likewise, median ages at diagnosis of 

components of LFS included at least nine (39%) Japanese patients, an ethnic group 
prone to this neoplasm (14, 19, 60, 64). Based on the small 
numbers of cases, it is unclear whether these neoplasms are due 
to the germ-line $p53$ mutations or chance. Despite previous 
suggestions that melanoma may be a component of LFS (86, 
87), melanomas comprised only 6 of the 738 primary cancers 
(0.8%) among our series of $p53$ mutation carriers and their first-degree relatives.

Because LFS and other hereditary cancer syndromes feature 
early-onset neoplasms, the ages at diagnosis of these 169 
cancers were compared with corresponding data on cancer 
incidence from the population-based SEER Program. The ages 
at site-specific cancer diagnosis were often two to three decades 

ture early-onset neoplasms, the ages at diagnosis of these 169 
cancers were compared with corresponding data on cancer 
incidence from the population-based SEER Program. The ages 
at site-specific cancer diagnosis were often two to three decades 

ture early-onset neoplasms, the ages at diagnosis of these 169 
cancers were compared with corresponding data on cancer 
incidence from the population-based SEER Program. The ages 
at site-specific cancer diagnosis were often two to three decades 

ture early-onset neoplasms, the ages at diagnosis of these 169 
cancers were compared with corresponding data on cancer 
incidence from the population-based SEER Program. The ages 
at site-specific cancer diagnosis were often two to three decades 

Table 1  Tumor spectrum in $p53$ mutation carriers and their first-degree relatives within 45 affected DF/NCI kindreds and 140 families in the literature

<table>
<thead>
<tr>
<th>Tumor types</th>
<th>Component tumors of LFS</th>
<th>Breast carcinoma</th>
<th>Soft tissue sarcoma</th>
<th>Brain tumors</th>
<th>Bone sarcoma</th>
<th>Adrenocortical carcinoma</th>
<th>Leukemia</th>
<th>Other tumors</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>DF/NCI cases</td>
<td>67</td>
<td>20</td>
<td>18</td>
<td>8</td>
<td>14</td>
<td>3</td>
<td>4</td>
<td>8</td>
<td>75</td>
</tr>
<tr>
<td>Literature cases</td>
<td>315</td>
<td>94</td>
<td>78</td>
<td>62</td>
<td>49</td>
<td>24</td>
<td>8</td>
<td>52</td>
<td>367</td>
</tr>
<tr>
<td>Both series</td>
<td>382</td>
<td>114</td>
<td>96</td>
<td>70</td>
<td>63</td>
<td>27</td>
<td>12</td>
<td>60</td>
<td>442</td>
</tr>
<tr>
<td>First-degree relativesa</td>
<td>84</td>
<td>30</td>
<td>15</td>
<td>23</td>
<td>10</td>
<td>2</td>
<td>4</td>
<td>60</td>
<td>124</td>
</tr>
<tr>
<td>Literature cases</td>
<td>103</td>
<td>45</td>
<td>13</td>
<td>22</td>
<td>16</td>
<td>3</td>
<td>3</td>
<td>69</td>
<td>28</td>
</tr>
<tr>
<td>Both series</td>
<td>187</td>
<td>75</td>
<td>28</td>
<td>45</td>
<td>26</td>
<td>8</td>
<td>5</td>
<td>109</td>
<td>124</td>
</tr>
<tr>
<td>Total</td>
<td>569</td>
<td>187</td>
<td>124</td>
<td>115</td>
<td>89</td>
<td>32</td>
<td>20</td>
<td>169</td>
<td>738</td>
</tr>
</tbody>
</table>

a Relatives with nearly 50% likelihood of a germ-line $p53$ mutation are parents, siblings, and offspring of carriers.

Table 2  Numbers of cancer cases, by tumor type and ages at diagnosis, in $p53$ carriers and their first-degree relatives, after excluding the 6 LFS-associated neoplasms

<table>
<thead>
<tr>
<th>Primary site</th>
<th>$p53$ mutation carriersb</th>
<th>First-degree relativesb</th>
<th>United States populatioc</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of cases</td>
<td>Median age at diagnosis (range) (yrs)</td>
<td>No. of cases</td>
</tr>
<tr>
<td>Lung</td>
<td>11</td>
<td>50 (18–63)</td>
<td>18</td>
</tr>
<tr>
<td>Stomach</td>
<td>8</td>
<td>35 (20–60)</td>
<td>15</td>
</tr>
<tr>
<td>Ovary</td>
<td>8</td>
<td>42 (21–56)</td>
<td>8</td>
</tr>
<tr>
<td>Colon/rectum</td>
<td>7</td>
<td>33 (9–64)</td>
<td>12</td>
</tr>
<tr>
<td>Lymphomas</td>
<td>4</td>
<td>25 (16–37)</td>
<td>11</td>
</tr>
<tr>
<td>Melanoma</td>
<td>3</td>
<td>35 (16–35)</td>
<td>3</td>
</tr>
<tr>
<td>Endometrium</td>
<td>2</td>
<td>50 (48–51)</td>
<td>1</td>
</tr>
<tr>
<td>Thyroid</td>
<td>2</td>
<td>37 (31–44)</td>
<td>3</td>
</tr>
<tr>
<td>Pancreas</td>
<td>1</td>
<td>49</td>
<td>2</td>
</tr>
<tr>
<td>Prostate</td>
<td>1</td>
<td>58</td>
<td>6</td>
</tr>
<tr>
<td>Cervix</td>
<td>1</td>
<td>30</td>
<td>3</td>
</tr>
<tr>
<td>Otherd</td>
<td>12</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>All types</td>
<td>60</td>
<td>109</td>
<td></td>
</tr>
</tbody>
</table>

a LFS-associated cancers: breast and adrenocortical carcinomas, sarcomas of bone and soft tissues, brain tumors, and acute leukemias.
b Combined data from 45 DF/NCI families and 140 additional kindreds in the literature.
d Other cancers include: carcinomas of the bladder (3), kidney (2), esophagus (3), and unknown primary site (2); hepatoblastoma (2); neuroblastoma (2); mesothelioma (2); and 23 other neoplasms, including rare carcinomas of the gall bladder, ampulla of Vater, ureter, and testis, and Wilms’ tumor (1 each).
stomach cancer were 36 years earlier in p53 mutation carriers and 34 years earlier in their first-degree relatives (median age at diagnosis in the general population, 71 years). The majority of these cancers in families with p53 mutations arose before age 50 years, when malignant neoplasms are relatively uncommon in the general population.

Analyses of the positions and types of germ-line p53 mutations showed that the majority of alterations were within the p53 binding domain that is encompassed by exons 5–8. However, many reports included in our review, particularly earlier publications, were limited to the analyses of exons 5–8 (12, 14, 18, 22, 26–43, 45–53, 55, 57–61, 66, 67, 69, 78–80, 82, 83). Therefore, our data likely underestimate the mutation frequency outside this domain. The distribution of cancers by primary site and histology did not vary with nucleotide position or type of germ-line p53 mutation, i.e., missense mutations, protein-truncating mutations, and mutations that alter RNA splicing.

Discussion
Several published reviews have sought genotype-phenotype correlations in families with germ-line p53 mutations (9, 10, 21). These reports focused primarily on the LFS-associated breast and adrenocortical carcinomas, sarcomas, brain tumors, and acute leukemias. In this study, we examined the occurrence of other types of cancer in p53 mutation carriers and their first-degree relatives with nearly 50% likelihood of being a carrier. Many other forms of cancer were found to occur among both p53 mutation carriers and their first-degree relatives with nearly 50% risk of carrying a germ-line p53 mutation. Moreover, these cancers occurred at early ages, a characteristic of virtually all hereditary cancers (Table 2; Ref. 88). The findings suggest that carcinomas of the stomach, colon, rectum, pancreas, and ovary and lymphomas may represent uncommon manifestations of germ-line p53 mutations. Because somatic p53 mutations are found in virtually all forms of sporadic cancer in humans, it is reasonable that germ-line p53 mutations would also predispose to a wide spectrum of tumors (89, 90).

Alternative explanations underlying our observations include: (a) selection of families with multiple early-onset cancers for p53 analysis; (b) more accurate diagnosis and recall of cancer deaths among younger relatives; and (c) a small effect of lead time bias due to increased medical surveillance among family members at high risk. In addition, our data on ages at cancer diagnosis were compared with SEER cancer incidence data for the United States population, whereas families with p53 mutations were from many different nations (11–83). However, these factors are unlikely to explain ages at diagnosis that were usually several decades earlier than those expected in the general population.

The original and subsequent descriptions of LFS included acute leukemias as a component of the syndrome (1, 2, 4–8). However, acute leukemias accounted for only 20 of the 738 cancers (2.7%) in the 185 kindreds, and germ-line p53 mutations are uncommon in familial clusters of acute leukemia (33). The data suggest that childhood leukemia may be a less common manifestation of germ-line p53 mutations than reported previously. The inclusion of acute leukemias in earlier descriptions of LFS might be due to the identification of affected families through medical record reviews of children with cancer, one-third of whom had acute leukemias (88).

Germ-line p53 mutations have been identified in more than one-half of the families who fulfill LFS criteria and in a smaller proportion of those with partial features of the syndrome. In addition, germ-line hCHK2 mutations were recently identified in three of our families: (a) one with classic features of LFS; (b) another with some features of LFS; and (c) a third patient with three primary cancers (91). Studies of additional families will help clarify the fraction of LFS attributable to germ-line CHK2 mutations and any phenotypic differences between p53 carriers and hCHK2 carriers.

Cancers in our study subjects were often treated with radiotherapy and chemotherapy, which have carcinogenic potential. We have previously reported that multiple primary cancers occurred with high frequency within LFS cancers and that radiation-associated sarcomas were common among the subsequent cancers (5). In the literature series, treatment data were too scanty for analyses of their carcinogenic influences.

The results of this study suggest that the elevated cancer susceptibility among p53 mutation carriers extends to a wider variety of neoplasms than previously recognized, with 23% of cancers falling outside the realm of the six classic LFS component tumors. Carriers of diverse germ-line p53 mutations appear to be at increased risk for carcinomas of the lung, gastrointestinal tract, and female reproductive organs, as well as lymphomas. Future high throughput technologies for genetic analyses will permit larger studies of unselected patients with various cancers, including those with early and later onset, to clarify the site-specific cancer risks associated with constitutional p53 mutations. Although cancer screening is hampered by the diversity of cancers developing in p53 mutation carriers and the low sensitivity of most screening tests, the survival experiences of LFS family members should improve with advances in chemoprevention and other interventions. In additional collaborative studies of LFS, it will be important to clarify the age-specific penetrance and risks of various cancers in carriers of hCHK2 as well as p53 germ-line mutations. These studies will help identify the host and environmental modifiers of risk and increase the utility of LFS as a model for understanding the role of p53 alterations in carcinogenesis and for designing diagnostic and preventive interventions for the broad array of neoplasms in this hereditary syndrome.

Acknowledgments
We thank Lisa DiGianni for help in providing family history information for the Dana Farber kindreds, Sig Verselis for p53 mutation analysis, and Jennifer Morgan and Nina Cardoza for technical support.

References
Hypothesis: Tumor Spectrum in LFS


Germ-line \textit{p53} Mutations Predispose to a Wide Spectrum of Early-onset Cancers

Kim E. Nichols, David Malkin, Judy E. Garber, et al.


\begin{itemize}
  \item \textbf{Updated version} Access the most recent version of this article at: http://cebp.aacrjournals.org/content/10/2/83
  \item \textbf{Cited articles} This article cites 84 articles, 27 of which you can access for free at: http://cebp.aacrjournals.org/content/10/2/83.full#ref-list-1
  \item \textbf{Citing articles} This article has been cited by 37 HighWire-hosted articles. Access the articles at: http://cebp.aacrjournals.org/content/10/2/83.full#related-urls
  \item \textbf{E-mail alerts} Sign up to receive free email-alerts related to this article or journal.
  \item \textbf{Reprints and Subscriptions} To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
  \item \textbf{Permissions} To request permission to re-use all or part of this article, use this link http://cebp.aacrjournals.org/content/10/2/83. Click on "Request Permissions" which will take you to the Copyright Clearance Center’s (CCC) Rightslink site.
\end{itemize}